BioDelivery Gets a Buy Rating from H.C. Wainwright

By Austin Angelo

In a report released today, Corey Davis from H.C. Wainwright reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $4. The company’s shares opened today at $2.95, close to its 52-week high of $3.10.

According to, Davis is a 3-star analyst with an average return of 3.1% and a 47.5% success rate. Davis covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Aquinox Pharmaceuticals, and Infotek Pharmaceuticals.

Currently, the analyst consensus on BioDelivery is Strong Buy and the average price target is $4.25, representing a 44.1% upside.

In a report issued on June 21, FBR Capital also reiterated a Buy rating on the stock.

The company has a one year high of $3.10 and a one year low of $1.50. Currently, BioDelivery has an average volume of 643.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.,002RGM-E